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Abstract
Introduction Alterations in cell cycle regulators have been
implicated in human malignancies including breast cancer. PD
0332991 is an orally active, highly selective inhibitor of the
cyclin D kinases (CDK)4 and CDK6 with ability to block
retinoblastoma (Rb) phosphorylation in the low nanomolar
range. To identify predictors of response, we determined the in
vitro sensitivity to PD 0332991 across a panel of molecularly
characterized human breast cancer cell lines.
Methods Forty-seven human breast cancer and immortalized
cell lines representing the known molecular subgroups of breast
cancer were treated with PD 0332991 to determine IC50 values.
These data were analyzed against baseline gene expression
data to identify genes associated with PD 0332991 response.
Results Cell lines representing luminal estrogen receptor-
positive (ER+) subtype (including those that are HER2
amplified) were most sensitive to growth inhibition by PD
0332991 while nonluminal/basal subtypes were most resistant.
Analysis of variance identified 450 differentially expressed
genes between sensitive and resistant cells. pRb and cyclin D1
were elevated and CDKN2A (p16) was decreased in the most
sensitive lines. Cell cycle analysis showed G0/G1  arrest in
sensitive cell lines and Western blot analysis demonstrated that
Rb phosphorylation is blocked in sensitive lines but not resistant
lines. PD 0332991 was synergistic with tamoxifen and
trastuzumab in ER+ and HER2-amplified cell lines, respectively.
PD 0332991 enhanced sensitivity to tamoxifen in cell lines with
conditioned resistance to ER blockade.
Conclusions These studies suggest a role for CDK4/6
inhibition in some breast cancers and identify criteria for patient
selection in clinical studies of PD 0332991.
Introduction
Breast cancer is a worldwide health concern with approxi-
mately 1,000,000 million new cases each year [1]. Significant
advances have been made in our understanding of this malig-
nancy and several molecular subtypes of breast cancer have
been characterized [2-4]. This molecular understanding has
paved the way for the development of new agents that target
pathogenic molecular alterations that drive tumor cell growth
while sparing patients many of the traditional toxicities associ-
ated with chemotherapy. Ubiquitous to all cancer types is
abnormal proliferation with dysregulation of normal cell cycle
control [5]. For this reason, inhibitors of key cell cycle regula-
tors are attractive targets for novel cancer therapeutics [6].
Successful clinical development of this class of agents, how-
ever, will require some understanding of which subgroup of
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patients will be more likely to benefit from these targeted inter-
ventions.
Under normal control, the cell cycle functions as a tightly reg-
ulated and predictable process consisting of several distinct
phases: G0 (quiescence) followed by G1 (pre-DNA synthesis),
S (DNA synthesis), G2 (pre-division), and M (cell division). The
careful regulation of this system is of fundamental importance,
and dysregulation can result in several disease processes
including cancer. The progression from G1 to S is a key check-
point in protecting the cell from abnormal replication. Key to
passage through this restriction point is the interaction
between the cyclin-dependent kinases (CDKs) and cyclin pro-
teins. CDKs are a subgroup of serine/threonine kinases that
play a key role in regulating cell cycle progression by associat-
ing with cyclins. Hyperphosphorylation of the retinoblastoma
(Rb) gene product pRb is mediated in early G1 by CDK4 and
CDK6 interacting with cyclin D1. This results in pRB inactiva-
tion and release of transcription factors that allow progression
to the S phase. Negative regulators of CDK4/6-cyclin activity
include the INK4 family (p16, p15, p18, p19) [7].
Several studies have identified alterations of cell cycle regula-
tors in human breast cancer (reviewed in [8,9]) and provide a
rationale for a potential therapeutic role for CDK4/6 inhibition
in this tumor type. Amplification of the cyclin D1 gene has been
identified in approximately 15 to 20% of human breast cancers
[10,11] while overexpression of the protein has been demon-
strated in a higher percentage [12,13]. The prognostic signif-
icance of cyclin D1 overexpression is not clear; some studies
suggest it is a dominant oncogene associated with poor clini-
cal outcomes [11,14-16], while other studies suggest it is
associated with a more indolent, estrogen receptor (ER)-pos-
itive phenotype [17,18]. In addition, studies have associated
cyclin D amplification with resistance to tamoxifen [19,20].
While the interaction between CDK4/6 and cyclin D1 sug-
gests their interdependence, cyclin D1 has been found to func-
tion independently of CDK4/6 in supporting proliferation by
directly activating ER [21,22]. Finally, loss of function of pRb
has been described in 20 to 35% of breast cancers (reviewed
in [23]).
The majority of CDK targeted agents to date have not focused
on CDK4/6 targeting but rather on CDK1/2 targeting. Conse-
quently the most advanced agents in development are aimed
at these targets [24,25]. Further, limited data exist regarding
the preclinical activity of CDK4/6 inhibitors in breast cancer.
PD 0332991 is an orally active potent and highly selective
inhibitor of CDK4 and CDK6 kinases, which in low nanomolar
concentrations blocks pRb phosphorylation - subsequently
inducing G1 arrest in sensitive cell lines [26-29]. Preclinical
studies have demonstrated that PD 0332991 induces G1
arrest in primary bone marrow cells ex vivo and prevents tumor
growth in disseminated human myeloma xenografts [30].
Based on the above biology, we hypothesized that there might
be a molecular subgroup of human breast cancers that would
be dependent on CDK4/6 function and would be likely to
respond to this agent. Previous studies have demonstrated
that in vitro large-panel analyses of molecularly characterized
breast cancer cell lines can offer insight into the molecular het-
erogeneity of the clinical disease [31,32]. To identify potential
biomarkers of response to PD 0332991 and to assist in
patient selection and clinical development, we therefore eval-
uated the effects of PD 0332991 in a panel of 47 human
breast cancer and immortalized breast cell lines growing in
vitro.
Materials and methods
Cell lines, cell culture, and reagents
The cell lines used in the analysis include MDA-MB-415,
MDA-MB-134, HCC-1500, ZR-75-30, HCC-202, HCC-
1419, HCC-38, HCC-70, HCC-1187, HCC-1806, HCC-
1937, HCC-1954, MDA-MB-436, HCC-1569, Hs578t, HCC-
1143, MDA-MB-175, BT-474, SK-BR-3, MDA-MB-361,
UACC-893, UACC-812, UACC-732, T-47D, MDA-MB-453,
MDA-MB-468, CAMA-1, MDA-MB-157, MCF-7, MDA-MB-
435, ZR-75-1, BT-20, MDA-MB-231, BT-549, DU4475,
HCC-1395, HCC-2218, 184A1, 184B5 and MCF-10A, and
were obtained from American Type Culture Collection (Rock-
ville, MD, USA). The cell lines EFM-192A, KPL-1, EFM-19,
COLO-824 and CAL-51 were obtained from the German Tis-
sue Repository DSMZ (Braunschweig, Germany), and the cell
lines SUM-190 and SUM-225 were obtained from the Univer-
sity of Michigan (Ann Arbor, MI, USA).
MDA-MB-134, MDA-MB-415, MDA-MB-436, MDA-MB-175,
UACC-893, UACC-812, and MDA-MB-157 cells were cul-
tured in L15 medium supplemented with 10% heat-inactivated
FBS, 2 mmol/l glutamine and 1% penicillin G-streptomycin-
fungizone solution (PSF) (Irvine Scientific, Santa Ana, CA,
USA). CAL-51, KPL-1, and Hs578t cells were grown in
DMEM (Cellgro, Manassas, VA, USA) supplemented with
10% heat-inactivated FBS and PSF, as above. SUM-190 and
SUM-225 cells were cultured in HAM's F12 supplemented
with 5% heat-inactivated FBS, PSF, 5 mg/ml insulin and 1 mg/
ml hydrocortisone. 184A1, 184B5, and MCF 10A cells were
grown in a 50/50 mix of mammary epithelial basal medium
(MCDB 170) (US Biological, Swampscott, MA, USA) supple-
mented with 1.5 ml/l bovine pituitary extract (Invitrogen,
Carlsbad, CA, USA), 20 μl/l epidermal growth factor (Invitro-
gen), 10 ml insulin (Sigma, Saint Louis, MO, USA), 1 ng/ml
cholera toxin (Calbiochem, San Diego, CA, USA), 0.5 mg/l
hydrocortisone (Sigma), and RPMI 1640 supplemented with
10% heat-inactivated FBS, 2 mmol/l glutamine, and 1% PSF.
The remaining cell lines were cultured in RPMI 1640 (Cellgro)
supplemented with 10% heat-inactivated FBS, 2 mmol/l
glutamine, and 1% PSF. A tamoxifen-resistant MCF7 cell line
was developed after serial passage in RPMI 1640 without
phenol red (Invitrogen) supplemented with 10% charcoal-Available online http://breast-cancer-research.com/content/11/5/R77
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stripped FBS (Fisher Scientific, Pittsburgh, PA, USA) and 2
mmol/l glutamine, and PSF.
Transcript microarray analyses
Briefly, cells were grown to log phase and then RNA was
extracted using the RNeasy Kit (Qiagen, Valencia, CA, USA).
The purified RNA was eluted in 30 to 60 μl diethylpyrocar-
bonate (DEPC) water and the quantity of RNA measured by
spectral analysis using the Nanodrop Spectrophotometer
(NanoDrop Products, Wilmington, DE, USA). RNA quality was
determined by separation of the RNA via capillary electro-
phoresis using the Agilent 2000 Bioanalyzer (Agilent Technol-
ogies, Santa Clara, CA, USA). Microarray hybridizations of 51
breast cell lines were performed using the Agilent Human 1A
V1 array.
Characterization of individual breast cancer cell line tran-
scripts was performed by comparison with a breast cell line
mixed reference pool of RNA and was conducted on a single
slide in which the cell line mixture RNA was labeled with cya-
nine-3 and RNA from the individual cell line was labeled with
cyanine-5. The mixed reference cRNA pool consisted of equal
amounts of cRNA from nine breast cancer cell lines and one
immortalized breast cell line selected to be representative of
the full spectrum of breast cancer subtypes based on their
expression of specific molecular markers - for example, ESR1,
HER2, epidermal growth factor receptor, cytokeratins, and so
forth - as well as growth characteristics. The reference cRNA
pool includes RNA from 184B5, MDA-MB-468, MDA-MB-
157, MDA-MB-231, MDA-MB-175, CAMA-1, MCF-7, MDA-
MB-361, SK-BR-3, and DU4475 cell lines.
Microarray slides were read using an Agilent Scanner, and
Agilent Feature Extraction software version 7.5 was used to
calculate gene expression values. The feature extracted files
were imported into the Rosetta Resolver® system version 7.1
for gene expression data analysis (Rosetta Biosoftware, Seat-
tle, WA, USA). The intensity ratios between the cell line sam-
ple and mixed reference calculated for each sequence were
computed according to the Agilent error model. A particular
sequence was considered differentially expressed if the calcu-
lated p-value of change was P ≤ 0.01. These data are available
with accession number [GEO:GSE18496].
Proliferation assays
Cells were seeded in duplicate at 5,000 to 10,000 cells per
well in 24-well plates. The day after plating, PD 0332991 was
added at 1 μM and twofold dilutions over six concentrations
were performed to generate a dose-response curve. Control
wells without drug were also seeded. Cells were counted on
day 1 when the drug was added as well as after 6 days when
the experiment ended. After trypsinization, cells were placed in
Isotone solution and counted immediately using a Coulter Z2
particle counter (Beckman Coulter Inc., Fullerton, CA, USA).
Suspension lines were counted using a Coulter Vi-Cell coun-
ter (Beckman Coulter Inc.).
Growth inhibition was calculated as a function of the number
of generations inhibited in the presence of PD 0332991 ver-
sus the number of generations over the same time course in
the absence of PD 0332991. In addition, lethality was defined
as any decrease in cell number in treated wells versus the
baseline number of cells pre-treatment at day 1 of exposure.
For tamoxifen studies with the MCF7 tamoxifen-resistant cell
line, proliferation studies were performed as above except
cells were plated without FBS and were supplemented with
0.5 nM β-estradiol (Sigma). Proliferation assays were then per-
formed as above.
Multiple drug effects analysis
Similar to above, the ER-positive cell lines MCF-7, T47-D, and
EFM-19 were plated and treated with PD 0332991 alone, with
4-hydroxytamoxifen (Sigma) alone, or with the combination, in
duplicate, over six twofold dilutions at a fixed molar ratio. For
combination studies with trastuzumab, BT-474, EFM-192A,
and MDA-361 lines were plated as above and treated with PD
0332991 alone, with trastuzumab (Genentech, South San
Francisco, CA, USA) alone, or with the combination, in dupli-
cate, over six twofold dilutions at a fixed molar ratio.
For each assay, the log of the fraction growth inhibition was
plotted against the log of drug concentration, and the linear
regression curve fit correlation coefficient (r value) was calcu-
lated. Multiple drug effect analysis was performed using com-
puter software as previously described [33].
Combination index (CI) values were derived from parameters
of the median effects plots, and statistical tests were applied
(unpaired, two-tail Student t test) to determine whether the
mean CI values at multiple concentrations were significantly
different from CI = 1. In this analysis, synergy is defined as CI
values significantly lower than 1.0, antagonism as CI values
significantly higher than 1.0, and additivity as CI values equal
to 1.0. All CI values were calculated using the conservative
assumption of mutually nonexclusive drug interactions. All
experiments were carried out at least twice. Combination stud-
ies were performed as above with the MCF7 tamoxifen-resist-
ant clones with addition of estrogen back to the media at the
time of the experiment (as described in cell culture above).
Western blot analysis
Cells in log-phase growth were treated with 100 nM PD
0332991 and were harvested at various timepoints by wash-
ing in PBS and lysis at 4°C in RIPA lysis buffer. Insoluble mate-
rial was cleared by centrifugation at 10,000 × g for 10 minutes
and protein was quantitated using bicinchoninic (BCA)
(Pierce Biochemicals, Rockford, IL, USA). Protein content was
resolved by SDS-PAGE electrophoresis, and was transferredBreast Cancer Research    Vol 11 No 5    Finn et al.
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to nitrocellulose membranes (Invitrogen). Total pRb expres-
sion was detected using a rabbit polyclonal antibody to pRb
(Abcam, Cambridge, MA, USA). Rb phosphorylation was
detected using rabbit polyclonal antibody to phospho-serine
780 (Cell-signaling, Danvers, MA, USA). Blots were washed
and incubated with a goat-anti-rabbit IgG horseradish peroxi-
dase conjugate (Upstate, Bellerica, MA, USA), developed
using ECL Plus chemifluorescent reagent (Amersham Bio-
sciences, Pistcataway, NJ), and imaged using chemifluores-
cence.
Cell cycle analysis and apoptosis studies
Effects of PD 0332991 on the cell cycle were assessed using
Nim-DAPI staining (NPE Systems, Pembroke Pines, FL, USA).
Cells were plated evenly in control and experimental wells,
were allowed to grow to log phase and were then treated with
100 nM PD 0332991 for the defined times. To perform cell
cycle analysis, cells were washed with PBS; then trypsin was
applied to release cells, which were then centrifuged at
10,000 × g for 5 minutes. Supernatant was aspirated and
cells were then resuspended in 100 μl Nim-DAPI (NPE Sys-
tems) and gently vortexed.
Cells were analyzed with UV using a Cell Lab Quanta SC flow
cytometer (Beckman-Coulter Inc.). Apoptosis assays were
performed using an Annexin V-FITC apoptosis detection kit
(MBL, Woburn, MA, USA) and flow cytometry. Cells were
plated and treated as for cell cycle studies and were exposed
to 100 nM PD 0332991 for 5 days. After incubation, cells
were processed as directed in the kit and were analyzed using
a FITC signal detector and propidium iodide detector using a
Cell Lab Quanta SC flow cytometer.
Statistical methods
Growth response to PD 0332991 and molecular subtype
classification data were entered into the Statistica data analy-
sis system version 8.0 (StatSoft Inc., Tulsa, OK, USA). The
Pearson chi-square test was used to assess the relationship
between response and subtype.
Breast cell lines were profiled on the Agilent Human 1A V1
platform that contains 17,086 probes including known genes
and ESTs. The Resolver system analysis of variance (ANOVA)
and hierarchical cluster analysis of the breast cell line expres-
sion profiles were used to compare the most sensitive cell
lines (n = 21, IC50 < 150 nM) and the most resistant cell lines
(n = 12, IC50 > 1,000 nM). All ANOVAs were performed using
the Benjamini-Hochberg False Discovery Rate (FDR) multiple
test correction and a statistical cutoff value for sequences of a
twofold change in at least three experiments. The criteria used
to determine differentially expressed genes were P < 0.05
with a difference between average expression for each group
of at least |0.2|. Sequence sets were compared using the
Venn Diagram tool in the Resolver system. The two-dimen-
sional cluster analysis was performed using an agglomerative
hierarchical clustering algorithm based on the cosine correla-
tion similarity metric.
Results
PD 0332991 inhibits growth of luminal ER-positive as 
well as HER2-amplified breast cancer cell lines
A total of 44 human breast cancer cell lines and three immor-
talized breast epithelial lines were categorized as representing
luminal or basal breast cancer subtypes based on the relative
gene expression of cytokeratin 8/cytokeratin 18 and cytokera-
tin 5/cytokeratin 17, respectively [31,32].
Several cell lines were further classified as representing breast
cancers that had undergone an epithelial-to-mesenchymal
transition based on their expression of vimentin and the loss of
cytokeratin expression. Some cell lines that demonstrated
mixed cytokeratin expression were classified as primarily basal
due to the lack of expression of several additional well-charac-
terized luminal markers, including ER, E-cadherin (CDH1), and
GATA3. The calculated IC50 for each cell line and its molecular
classification as well as the ER status and HER2 amplification
status was determined (Table 1 and Figure 1).
There was a statistically significant correlation between molec-
ular subtype and sensitivity to PD 0332991 (χ2 < 0.05). The
subtypes most sensitive to growth inhibition by PD 0332991
were ER-positive. In addition, 10/16 HER2-amplified cell lines
were sensitive. PD 0332991 inhibited growth in a cytostatic
manner in these cells with no lethality observed (data not
shown).
Identification of differentially expressed genes and 
sensitivity to PD 0332991
Gene expression profiles were used to identify genes associ-
ated with response to PD 0332991. A set of 450 differentially
expressed genes (P < 0.05, |sensitive group average - resist-
ant group average| ≥ 0.2) was identified, where 253 genes
were upregulated in sensitive cell lines and 197 genes were
upregulated in resistant lines. Hierarchical clustering of the 43
cell lines across these 450 differentially expressed genes was
performed (Figure 2).
A significant overlap was found between the gene set associ-
ated with response to PD 0332991 and the gene set that
defines breast cancer cell subtypes. Of the genes more highly
expressed in the sensitive cell lines, 193/253 (76%) are lumi-
nal markers and 0/253 are nonluminal markers. In the resistant
gene set, 117/197 (59%) are nonluminal markers and 0/197
are luminal markers. RB1, cyclin D1, and CDKN2A (p16) were
differentially expressed - with higher levels of RB1 and cyclin
D1, and lower levels of p16, in the sensitive group. Of note,
these three genes are cyclin related and are not in the breast
cell type gene set.Available online http://breast-cancer-research.com/content/11/5/R77
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Full results of the ANOVA with the exact genes and Venn dia-
grams demonstrating the overlap between the cell classifica-
tion markers and response markers are available online (see
Additional data files 1, 2, and 3). Importantly, both MCF-10A
and HCC-38 - sensitive cell lines that are of nonluminal origin
- cluster with the remaining sensitive lines when this operation
is performed excluding the subtype marker set (see Additional
data file 4), highlighting the robustness of the predictive
marker set.
PD 0332991 inhibits pRb phosphorylation in sensitive 
cell lines
It is known that CDK4/6 complexes with cyclin D1 to phospho-
rylate and inactivate pRb, thus allowing cell cycle progression.
The effects of PD 0332991 on total pRb and Rb phosphoryla-
tion were determined using Western blot analysis of a subset
of lines with variable sensitivities to PD 0332991.
There was no decrease in total pRB in either the sensitive
group or the resistant group after treatment with the CDK4/6
inhibitor (Figure 3a). There were significant differences, how-
ever, in Rb phosphorylation when comparing sensitive and
resistant cells after exposure to the compound. There was a
rapid and sustained decrease in pRb with exposure to 100 nM
PD 0332991 in the three more sensitive cell lines (Figure 3b).
The majority of the less sensitive lines have lower amounts of
total Rb, as determined by the microarray data; however, three
resistant cell lines that have detectable Rb but are still resist-
ant to PD 0332991 were also evaluated. These lines did not
have a significant decrease in Rb phosphorylation with 100
nM PD 0332991.
Effects of PD 0332991 on cell cycle and apoptosis
To evaluate the effects of PD 0332991 on the cell cycle and
to correlate them with the antiproliferative effects of the com-
pound, we treated a subset of both sensitive cell lines and
resistant cell lines with PD 0332991 at 100 nM for 48 hours
and then performed flow cytometry using Nim-DAPI staining.
Clear and pronounced G0/G1 arrest was seen in cell lines that
had lower IC50 values (IC50 < 150 nM) compared with those
with higher IC50 values (IC50 > 1,000 nM) (Figure 4). There
was no evidence of apoptosis in even the most sensitive cell
lines when PD 0332991 was used as a single agent (data not
shown).
Together, these data support a proposed cytostatic mecha-
nism of action of this CDK4/6 inhibitor involving prevention of
cell cycle progression by blocking hyperphosphorylation of
pRb.
Combinations of PD 0332991 plus tamoxifen and PD 
0332991 plus trastuzumab in ER-positive and HER2-
amplified breast cancer cells, respectively
Given that both the ER-positive cell lines as well as HER2-
amplified cell lines within the panel demonstrated greatest
sensitivity to PD 0332991, the combination of targeted thera-
peutics plus the CDK4/6 inhibitor was evaluated in both of
these molecular subtypes. In ER-positive breast cancer, hor-
monal blockade with tamoxifen is an effective treatment for
early and advanced disease. For the three ER-positive lines
evaluated, when considering the entire dose-response curve,
the combination was synergistic with mean CI < 1 across clin-
ically relevant concentrations of both drugs (Figure 5a).
Effects of the combination on the cell cycle are shown in Addi-
tional data file 5.
Figure 1
Inhibitory concentration and cell type Inhibitory concentration and cell type. Bar graph of IC50 values (nM) and cell type. Cell lines are color coded by subtype: light blue, luminal; dark blue 
bars or stripes, HER2 amplified; yellow, nonluminal/undergone an epithelial-to-mesenchymal transition; red, nonluminal; turquoise, immortalized.Breast Cancer Research    Vol 11 No 5    Finn et al.
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Table 1
Cell lines arranged from most sensitive (low IC50) to least sensitive (high IC50)
Cell line IC50value (nM) IC50standard error Breast cancer subtype ER status HER2 status
MDA-MB-175 4 0.4 Luminal Positive Normal
ZR-75-30 5 0.5 Luminal Positive Amplified
CAMA-1 8 0.4 Luminal Positive Normal
MDA-MB-134 13 1.3 Luminal Positive Normal
HCC-202 21 2.3 Luminal Positive Amplified
UACC-893 24 1.6 Luminal Positive Amplified
EFM-19 27 12.3 Luminal Positive Normal
SUM-190 28 1.3 Luminal Positive Amplified
EFM-192A 42 21.2 Luminal Positive Amplified
MDA-MB-361 44 4.1 Luminal Positive Amplified
HCC-1500 45 22.6 Luminal Positive Normal
HCC-1419 51 3.7 Luminal Positive Amplified
HCC-38 64 14.8 Basal Negative Normal
MDA-MB-415 64 6.6 Luminal Positive Normal
MCF-10A 92 0.1 n/a Negative Immortalized
UACC-812 96 4.6 Luminal Positive Amplified
HCC-2218 100 17.0 Luminal Positive Amplified
ZR-75-1 110 54.1 Luminal Positive Normal
MDA-MB-453 115 1.4 Luminal Negative Amplified
184A1 118 2.0 n/a Negative Immortalized
T47-D 127 15.0 Luminal Positive Normal
MCF-7 148 25.7 Luminal Positive Normal
BT-20 177 3.1 Basal Negative Normal
MDA-MB-435 201 7.5 Post-EMT Negative Normal
BT-474 240 64.5 Luminal Positive Amplified
SK-BR-3 300 83.0 Luminal Negative Amplified
KPL-1 327 64.3 Luminal Positive Normal
HCC-1143 359 99.7 Basal Negative Normal
MDA-MB-231 432 16.1 Post-EMT Negative Normal
HCC-1395 472 39.8 Post-EMT Negative Normal
SUM-225 503 55.7 Luminal Negative Amplified
Hs578t 524 12.3 Post-EMT Negative Normal
184B5 538 41.1 n/a Negative Immortalized
UACC-732 744 14.9 Luminal Positive Amplified
CAL-51 905 0.0 Post-EMT Negative Normal
BT-549 1,000 n/a Post-EMT Negative Normal
COLO-824 1,000 n/a Basal Negative Normal
DU4475 1,000 n/a Basal Negative Normal
HCC-1187 1,000 n/a Basal Negative Normal
HCC-1569 1,000 n/a Post-EMT Negative Amplified
HCC-1806 1,000 n/a Basal Negative Normal
HCC-1937 1,000 n/a Post-EMT Negative Normal
HCC-1954 1,000 n/a Basal Negative Amplified
HCC-70 1,000 n/a Basal Negative Normal
MDA-MB-436 1,000 n/a Post-EMT Negative Normal
MDA-MB-157 1,000 n/a Post-EMT Negative Normal
MDA-MB-468 1,000 n/a Basal Negative Normal
Included are molecular subtype and estrogen receptor (ER) and HER2 status. Cell lines representing the luminal ER-positive subtype were most 
sensitive to the growth inhibition effects of PD 0332991. n/a, not applicable; Post-EMT, cell lines classified as representing breast cancers that 
had undergone an epithelial-to-mesenchymal transition.Available online http://breast-cancer-research.com/content/11/5/R77
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Trastuzumab has been shown to have clinical activity in HER2-
amplified breast cancer [34]. For the three HER2-amplified
lines evaluated, again when considering the entire dose-
response curve, the combination also proved to be synergistic
with mean CI < 1 across clinically relevant concentrations of
both drugs (Figure 5b). Effects of the combination on the cell
cycle are shown in Additional data file 6.
PD 0332991 overcomes acquired resistance to tamoxifen
The MCF7 tamoxifen-resistant cell line has acquired tamoxifen
resistance after serial passages in estrogen-free conditions.
These MCF7 tamoxifen-resistant cells demonstrated sensitiv-
ity to monotherapy with PD 0332991. Treatment with PD
0332991 also enhanced sensitivity to tamoxifen in the resist-
ant cells when the two agents were used in combination,
although not restoring them to the level of the parental line
(Figure 6).
Discussion
The critical role of CDK-cyclin interactions in controlling cell
growth has been an attractive target in cancer therapy for
sometime. These data represent the most comprehensive pre-
clinical evaluation of a CDK4/6 inhibitor in breast cancer cell
lines to date, and build the case for its clinical development in
specific molecular subgroups of breast cancer.
Using baseline Agilent gene expression profiles, we first dem-
onstrated that luminal ER-positive and HER2-amplified breast
cancer cell lines were more sensitive to CDK4/6 inhibition of
proliferation and cell cycle arrest. ANOVA analysis of these
data identified a set of genes that were associated with
Figure 2
Differentially expressed genes between sensitive and resistant cell lines Differentially expressed genes between sensitive and resistant cell lines. Results of analysis of variance (ANOVA) identifying 450 differentially 
expressed genes between sensitive cell lines (IC50 < 150 nM) and resistant cell lines (IC50 > 1,000 nM). Retinoblastoma and cyclin D1 expression 
were higher in, and CDKN2A (p16) was lower in, sensitive cell lines. Full results of the ANOVA are available in the Additional data files.Breast Cancer Research    Vol 11 No 5    Finn et al.
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response to PD 0332991. While the majority of these genes
were associated with the luminal subtype, increased RB1 and
cyclin D1 as well as decreased CDKN2A (p16) were associ-
ated with sensitivity to the effects of PD 0332991 on the cell
cycle and growth inhibition. Western blot analysis confirmed
that Rb phosphorylation is decreased in sensitive cell lines
after PD 0332991 treatment, while resistant lines that had
detectable pRb were relatively resistant to the effects of PD
0332991 on Rb phosphorylation. In this case, the presence of
pRb alone is not predictive of response to PD 0332991. pRb
presence in the background of luminal ER-positive breast can-
cer, however, is predictive of response to the compound. pRb
is present in some nonluminal breast cancer cell lines but
these lines are resistant to both the antiproliferative effects of
PD 0332991 and its ability to block Rb hyperphosphorylation.
Further studies will be required to determine why PD
0332991 cannot block hyperphosphorylation in cell lines that
do contain pRb. One can speculate that potentially CDK4/6 is
mutated in these cell lines and does not allow PD 0332991
binding and kinase inhibition, as is the case in resistance to
BCR-ABL inhibitors in chronic myelogenous leukemia [35].
Alternatively, there may be another mechanism driving Rb
hyperphosphorylation in resistant cell lines, such as a greater
dependence on CDK1/2-cyclin E interactions or loss of nega-
tive regulators of this pathway in these cell lines.
Resistance to PD 0332991 in many of the nonluminal breast
cancer cell lines may be explained by the absence of pRb.
Recent publications highlighted the lack of pRb in basal-like
breast cancer tissue [36] and observed that pRb depletion
can result in the characteristic epithelial-to-mesenchymal tran-
sition changes seen in some breast cancer specimens [37],
recapitulating our in vitro observations. The lack of activity of a
CDK4/6 inhibitor in cell lines and tumors that lack pRb can be
explained by the fact that cyclin D1 does not offer G1 control in
the absence of pRb [38].
Published studies evaluating the role of cyclin D1 in breast can-
cer support the current observations of the activity of a CDK4/
6 inhibitor in luminal ER-positive breast cancer, its synergism
with tamoxifen in cell lines that are sensitive to hormone manip-
ulation, as well as the reversal of resistance of those that have
acquired a resistant phenotype in the face of anti-estrogen
therapy. Estrogen effects on cell cycle progression are tightly
linked to expression of cyclin D1 [39]. Cyclin D1 amplification
and/or overexpression has been more commonly associated
with an ER-positive breast cancer subtype [40] and, as men-
tioned previously, is associated with tamoxifen resistance
[19,20]. Some studies suggest that overexpression of cyclin
D1 can directly activate ER in a hormonally independent man-
ner that is also independent of CDK and pRb function [21,22].
The data supporting this concept were reviewed recently [41].
Figure 3
Effects of PD 0332991 on phosphorylation of retinoblastoma gene product Effects of PD 0332991 on phosphorylation of retinoblastoma gene product. PD 0332991 blocks phosphorylation of retinoblastoma gene product 
pRb in sensitive cell lines but not in resistant cell lines. (a) In neither group does total pRb change significantly with treatment. (b) PD 0332991 sig-
nificantly blocks phoshorylation of pRb (phospho-Rb) at serine 780 in sensitive cell lines (IC50 < 150 nM), but not in resistant cell lines (IC50 > 1,000 
nM). All cell lines were treated with 100 nM PD 0332991 for the times specified and western blots were performed as described in Materials and 
methods.Available online http://breast-cancer-research.com/content/11/5/R77
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In the large panel of human breast cancer lines we evaluated,
however, 9/10 ER-positive lines were sensitive to PD
0332991 inhibition. Of interest, Wang and colleagues
recently described a cyclin D1 splice variant - named cyclin D1b
- that occurs in breast cancer tissue and cell lines, and whose
expression can overcome cell cycle arrest induced by anti-
estrogens via a CDK4 interaction [42].
In addition, a pivotal role for cyclin D1 function in HER2-medi-
ated transformation has been described using transgenic
mouse models [43]. More recently, the same authors defined
that the ability of cyclin D1 to activate CDK4 is critical for driv-
ing tumorigenesis in these models. Moreover, CDK4-associ-
ated kinase activity is required to maintain breast
tumorigenesis in this system [44,45] and a subset (~25%) of
HER2-amplified breast cancers also have high cyclin D1 levels.
The authors hypothesized that this 'subset may benefit from
inhibiting CDK4 kinase' [44]. Our data would suggest that the
benefit with PD 0332991 might be extended beyond that
25%, since the benefit was not dependent on elevated cyclin
D1 alone in the HER2-amplified cell lines. In addition, synergis-
tic efficacy was observed between trastuzumab and PD
0332991 that may also be independent of cyclin D1 measure-
ment. Earlier work evaluating the nonspecific cyclin-CDK
inhibitor flavopiridol in combination with trastuzumab also
demonstrated similar activity in HER2-amplified cell lines [46].
Finally, a recent study investigating gene expression profiles of
women with HER2-amplified breast cancer who develop early
brain metastasis identified CDK4 expression as part of a 13-
gene profile that predicted for early brain metastasis and death
[47].
Acquired and de novo resistance to trastuzumab remains a
management challenge in clinical oncology. While limited data
Figure 4
Effects of PD 0332991 on cell cycle Effects of PD 0332991 on cell cycle. (a) Sensitive cell lines (IC50 < 150 nM) show marked G0/G1 arrest and a decrease in the S-phase fraction as 
compared with (b) resistant cell lines (IC50 > 1,000 nM) after incubation with 100 nM PD 0332991 for 24 hours. Solid bars, control samples; 
hatched bars, treated samples. Error bars represent the standard error for two separate experiments.Breast Cancer Research    Vol 11 No 5    Finn et al.
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Figure 5
Effects of PD 0332991, tamoxifen, and trastuzumab on growth of breast cancer cell lines Effects of PD 0332991, tamoxifen, and trastuzumab on growth of breast cancer cell lines. PD 0332991 (PD) acts synergistically with tamoxifen 
(Tam) and trastuzumab in inhibiting growth of (a) estrogen receptor-positive human breast cancer cell lines and (b) HER2-amplified cell lines in vitro, 
respectively. (a) Grey squares, PD 0332991 alone; open diamonds, tamoxifen alone; dark triangles, PD 0332991 and tamoxifen combination. (b) 
Grey squares, PD 0332991 alone; open diamonds, trastuzumab alone; dark triangles, PD 0332991 and trastuzumab combination. Error bars repre-
sent the standard error for two separate experiments. Mean combination index (CIm) for the combination curves shown with standard error CIm < 1, 
indicating synergy for the combinations.Available online http://breast-cancer-research.com/content/11/5/R77
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exist about the role of CDK4-cyclin D1 interactions and trastu-
zumab resistance, these data suggest a role for dual targeting
of the HER2 pathway and CDK4/6. Molecular profiling of the
JIMT-1 human breast cancer cell line derived from a woman
with progressive HER2-amplified disease while receiving tras-
tuzumab did identify a small amplicon on 12q14.1, which con-
tains the CDK4 gene [48].
Conclusions
The goal of this preclinical study was to guide patient selection
as this novel agent moves into the clinic. Given the data from
the current study as well as published work, there is a strong
rationale for clinical development of PD 0332991 focusing on
ER-positive luminal breast cancer as well as HER2-amplified
disease and combining CDK4/6 inhibition with anti-estrogen
or anti-HER2 therapy, respectively.
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